Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy

被引：3

作者：

Wu, Jiyong ^{[1
]}

Nie, Jing ^{[1
]}

Luan, Yepeng ^{[2
]}

Ding, Yanjiao ^{[1
]}

机构：

[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China

[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2023年 / 30卷 / 20期

基金：

美国国家科学基金会;

关键词：

Histone deacetylase; hybrid; multitarget inhibitors; antitumor; cancer therapy; bifunctional agent; SHOCK-PROTEIN; 90; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE NAMPT; HYDROXAMIC ACID-DERIVATIVES; BETA-CARBOLINE ALKALOIDS; NITRIC-OXIDE DONORS; IN-VITRO EVALUATION; DEMETHYLASE; LSD1; PROSTATE-CANCER; HDAC INHIBITORS; ANDROGEN RECEPTOR;

D O I：

10.2174/0929867329666220826163626

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Inhibition of histone deacetylases (HDACs) has proven to be an effective strategy for cancer therapy. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. An agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDACi. Representative classes of reported hybrid HDACis are reviewed here to shed light on the design of novel hybrid HDACis for cancer therapy.

引用

页码：2267 / 2311

页数：45

共 50 条

[31] Targeted histone deacetylase inhibition for cancer therapy
Vigushin, DM
Coombes, RC
CURRENT CANCER DRUG TARGETS, 2004, 4 (02) : 205 - 218
[32] Recent histone deacetylase inhibitors in cancer therapy
Parveen, Roza
Harihar, Divya
Chatterji, Biswa Prasun
CANCER, 2023, 129 (21) : 3372 - 3380
[33] Histone deacetylase inhibitors for epigenetic therapy of cancer
Monneret, Claude
ANTI-CANCER DRUGS, 2007, 18 (04) : 363 - 370
[34] Class I Histone Deacetylase Inhibitor Therapy in the Treatment of Hepatoblastoma
Whitlock, R.
Srivastava, R.
Patel, R.
Larson, S.
Woodfield, S.
Vasudevan, S.
PEDIATRIC BLOOD & CANCER, 2021, 68 : S273 - S273
[35] Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy
Piekarz, Richard L.
Sackett, Dan L.
Bates, Susan E.
CANCER JOURNAL, 2007, 13 (01): : 30 - 39
[36] Development of a Novel Ferrocenyl Histone Deacetylase Inhibitor for Triple-Negative Breast Cancer Therapy
Tang, Chu
Du, Yang
Liang, Qian
Cheng, Zhen
Tian, Jie
ORGANOMETALLICS, 2018, 37 (14) : 2368 - 2375
[37] Harnessing epigenetic reprogramming by histone deacetylase inhibitor MS275 for pancreatic cancer therapy
Liang, Gaoyang
Yu, Ruth
Liddle, Christopher
Truitt, Morgan
Antal, Corina
Atkins, Annette
Banayo, Ester
Downes, Michael
Evans, Ronald
CANCER RESEARCH, 2017, 77
[38] The potential of histone deacetylase inhibitors in breast cancer therapy
Chatterjee, Namita
Tenniswood, Martin
BREAST CANCER MANAGEMENT, 2015, 4 (02) : 85 - 97
[39] Recent advances in histone deacetylase targeted cancer therapy
Isamu Hoshino
Hisahiro Matsubara
Surgery Today, 2010, 40 : 809 - 815
[40] Histone deacetylase inhibitors in the therapy of cancer: much to learn
Lee, Ju-Hee
Marks, Paul A.
EPIGENOMICS, 2010, 2 (06) : 723 - 725

← 1 2 3 4 5 →